Data completeness
3/8 — Basic
DAPTOMYCIN (daptomycin) by Pfizer is [see clinical pharmacology ()] . Approved for bacteremia, soft tissue infections, skin infections and 10 more indications.
Drug data last refreshed 2w ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Daptomycin is an intravenous cyclic lipopeptide antibiotic that treats serious gram-positive bacterial infections including bacteremia, endocarditis, skin and soft tissue infections, and osteomyelitis. It works by disrupting bacterial cell membrane integrity and inhibiting protein synthesis. The drug is particularly valuable for methicillin-resistant Staphylococcus aureus (MRSA) and other resistant gram-positive pathogens.
Pre-Launch (Pfizer branded product)
Pfizer's pre-launch daptomycin represents a strategic entry into the IV antibiotic market with established clinical utility, suggesting commercial team buildout for hospital sales and infectious disease engagement.
Mechanism of Action
[see Clinical Pharmacology ()] .
Worked on DAPTOMYCIN at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.